Cancer volume 124, issue 12, P2523-2533 2018 DOI: 10.1002/cncr.31354 View Full Text
|
|
Share
Tomasz Czerw, Myriam Labopin, Sebastian Giebel, Gérard Socié, Liisa Volin, Nathalie Fegueux, Tamás Masszi, Didier Blaise, Sridhar Chaganti, Jan J. Cornelissen, Jakob Passweg, Johan Maertens, Maija Itälä-Remes, Depei Wu et al.

Abstract: Patients with Ph-neg ALL treated with allo-PBSCT benefit from the use of ATG in terms of improved GRFS. Its use may, therefore, be considered in this setting. Cancer 2018;124:2523-33. © 2018 American Cancer Society.

Filters

Filter received citations by the textual context, citing paper title, authors, etc.

Citation Types

0
7
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship beta

0
0